Merck Finalizes $10.8B Prometheus Buy

Merck has finalized its acquisition of Prometheus Biosciences for $10.8 billion, gaining five candidates for inflammatory bowel and immune-mediated diseases, including the leading candidate MK-7240 for ulcerative colitis and Crohn's disease. The purchase marks Merck's further expansion into the immunology space. The all-cash agreement includes buying all outstanding shares of Prometheus at a 75%..